Furthermore, IGF2BP2 overexpression is associated with abnormal structural changes in cardiomyocytes post-MI, such as mitochondrial fragmentation and sarcomere thinning, suggesting that IGF2BP2 may play a pivotal role in MI pathology and could serve as a key therapeutic target in the future [57]. The gene discussed is IGF2BP2; the disease is myocardial infarction.